[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.16.17.16. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 1974

Safety of Megadosage Haloprogin

Author Affiliations

From St. Jude Children's Research Hospital, Memphis (Drs. Hughes and Feldman), and the Medical Research Division, Mead Johnson Co., Evansville, Ind (Dr. Hermann).

Arch Dermatol. 1974;110(6):926-928. doi:10.1001/archderm.1974.01630120072018
Abstract

A 4-year-old girl with unremitting chronic mucocutaneous candidiasis since 9 months of age was treated topically with haloprogin for a total of 460 days in seven periods of consecutive weeks to months over a 3-year span. During that time, she was given 403 tubes or bottles (30 gm or ml) amounting to about 12,090 gm of a product containing 1% haloprogin. Biochemical, hematologic, and urine examinations were used in monitoring the patient's condition during treatment and showed no evidence of systemic or dermal toxicity.

×